Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial

Jacques P. Brown, Klaus Engelke, Tony M. Keaveny, Arkadi Chines, Roland Chapurlat, A. Joseph Foldes, Xavier Nogues, Roberto Civitelli, Tobias De Villiers, Fabio Massari, Cristiano A.F. Zerbini, Zhenxun Wang, Mary K. Oates, Christopher Recknor, Cesar Libanati

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences